# MiRagen Therapeutics (Viridian Therapeutics)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/miragen-therapeutics-viridian-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.miragen.com
- Total disclosed funding: $75M
- Latest round: Series C (Nov 10, 2015)
- Investors on record: 10

## About

Founded in 2007 and based in Colorado, US, Viridian Therapeutics, Inc. formerly known as MiRagen Therapeutics, Inc. operates as a biotechnology company that develops cardiovascular and muscle disease therapeutics based on microRNA biology. In January 2024, Viridian Therapeutics, Inc. raised USD 150 million in a private placement, selling 7.14 million shares at USD 21 per share on the Nasdaq Global Select Market under the ticker symbol VRDN. The firm, as of July 2024, has offices in Massachusetts and Colorado, US, and is led by its President and CEO, Steve Mahoney.

Viridian Therapeutics develops therapies for patients with autoimmune and rare diseases. The company's portfolio includes a pipeline of investigational therapeutic candidates. Central to their efforts is a focus on thyroid eye disease (TED), exemplified by their candidate, VRDN-001, currently in pivotal Phase 3 trials (THRIVE and THRIVE-2). These studies aim to evaluate the drug's efficacy and safety for patients with active and chronic TED. Additionally, VRDN-003, another candidate, offers a promising subcutaneous therapy option, with plans underway for its own Phase 3 program (REVEAL-1 and REVEAL-2). Other pipeline products include VRDN-006 and VRDN-008, which hold potential across multiple autoimmune diseases. 

The company plans to utilize the January 2024 funding to further its clinical development programs, as well as for working capital and general corporate purposes.

## Funding rounds

- Series C, Nov 10, 2015, $41M — Atlas Venture, Boulder Ventures, Amgen Ventures, JAFCO Group, Merck Global Health Innovation Fund, MP Healthcare Venture Management, Remeditex Ventures, Brace Pharma Capital
- Series B, Feb 17, 2015, $8.5M — Atlas Venture, Boulder Ventures, Amgen Ventures, Broadview Ventures, Remeditex Ventures
- Series B, Jun 27, 2014, $7M — Atlas Venture, Boulder Ventures, Amgen Ventures, Broadview Ventures, Remeditex Ventures
- Series B, Apr 10, 2012, $6M — Atlas Venture, Boulder Ventures, Amgen Ventures, Broadview Ventures, Remeditex Ventures
- Series B, Jun 3, 2009, $4M — Peierls Foundation, Amgen Ventures, Broadview Ventures
- Series A, May 19, 2008, $8M — Atlas Venture, Boulder Ventures

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B, Series C
- Boulder Ventures (https://capitalatlas.ai/funds/boulder-ventures) — Series A, Series B, Series C
- Peierls Foundation — Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B, Series C
- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Series B
- Remeditex Ventures (https://capitalatlas.ai/funds/remeditex-ventures) — Series B, Series C
- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series C
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series C
- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Series C
- Brace Pharma Capital (https://capitalatlas.ai/funds/brace-pharma-capital) — Series C